RARE
Income statement / Annual
Last year (2024), Ultragenyx Pharmaceutical Inc.'s total revenue was $560.23 M,
an increase of 29.01% from the previous year.
In 2024, Ultragenyx Pharmaceutical Inc.'s net income was -$569.18 M.
See Ultragenyx Pharmaceutical Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$560.23 M |
$434.25 M |
$363.33 M |
$351.41 M |
$271.03 M |
$103.71 M |
$51.50 M |
$2.61 M |
$133,000.00 |
$0.00 |
| Cost of Revenue |
$76.73 M
|
$45.21 M
|
$28.32 M
|
$16.01 M
|
$6.13 M
|
$9.01 M
|
$1.15 M
|
$1,000.00
|
$183.20 M
|
$1.38 M
|
| Gross Profit |
$483.50 M
|
$389.04 M
|
$335.01 M
|
$335.40 M
|
$264.90 M
|
$94.71 M
|
$50.35 M
|
$2.61 M
|
-$183.07 M
|
-$1.38 M
|
| Gross Profit Ratio |
0.86
|
0.9
|
0.92
|
0.95
|
0.98
|
0.91
|
0.98
|
1
|
-1376.47
|
0
|
| Research and Development Expenses |
$697.87 M
|
$648.45 M
|
$705.79 M
|
$497.15 M
|
$412.08 M
|
$357.36 M
|
$294.00 M
|
$231.64 M
|
$183.20 M
|
$114.74 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$127.72 M
|
$99.91 M
|
$64.94 M
|
$33.00 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$321.61 M
|
$309.80 M
|
$278.14 M
|
$219.98 M
|
$182.93 M
|
$161.52 M
|
$127.72 M
|
$99.91 M
|
$64.94 M
|
$33.00 M
|
| Other Expenses |
$0.00
|
$0.00
|
$9.51 M
|
$241,000.00
|
$7.65 M
|
$12.45 M
|
$3.95 M
|
$10.60 M
|
$2.17 M
|
-$200,000.00
|
| Operating Expenses |
$1.02 B
|
$958.25 M
|
$983.93 M
|
$717.14 M
|
$595.02 M
|
$518.88 M
|
$421.72 M
|
$331.55 M
|
$248.14 M
|
$147.74 M
|
| Cost And Expenses |
$1.10 B
|
$1.00 B
|
$1.01 B
|
$733.14 M
|
$601.15 M
|
$527.89 M
|
$422.87 M
|
$331.55 M
|
$248.14 M
|
$147.74 M
|
| Interest Income |
$36.51 M
|
$26.69 M
|
$11.07 M
|
$1.93 M
|
$7.04 M
|
$13.24 M
|
$9.54 M
|
$4.07 M
|
$3.79 M
|
$2.32 M
|
| Interest Expense |
$63.04 M
|
$66.00 M
|
$43.02 M
|
$29.42 M
|
$33.29 M
|
$1.14 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$35.54 M
|
$26.01 M
|
$18.20 M
|
$13.24 M
|
$12.26 M
|
$8.54 M
|
$19.54 M
|
$5.83 M
|
$3.42 M
|
$1.38 M
|
| EBITDA |
-$469.00 M |
-$516.45 M |
-$640.51 M |
-$410.32 M |
-$139.81 M |
-$389.77 M |
-$177.56 M |
-$312.51 M |
-$244.58 M |
-$146.35 M |
| EBITDA Ratio |
-0.84
|
-1.19
|
-1.76
|
-1.09
|
-1.19
|
-3.97
|
-10.52
|
-125.93
|
-1864.71
|
0
|
| Operating Income Ratio |
-0.96
|
-1.31
|
-1.79
|
-1.09
|
-1.22
|
-4.09
|
-7.21
|
-125.93
|
-1864.71
|
0
|
| Total Other Income/Expenses Net |
-$31.61 M
|
-$39.26 M
|
-$52.81 M
|
-$71.24 M
|
$144.76 M
|
$24.73 M
|
$174.28 M
|
$10.60 M
|
$2.17 M
|
$2.12 M
|
| Income Before Tax |
-$567.59 M
|
-$608.46 M
|
-$701.73 M
|
-$452.98 M
|
-$185.36 M
|
-$399.44 M
|
-$197.10 M
|
-$318.34 M
|
-$245.84 M
|
-$145.62 M
|
| Income Before Tax Ratio |
-1.01
|
-1.4
|
-1.93
|
-1.29
|
-0.68
|
-3.85
|
-3.83
|
-121.88
|
-1848.41
|
0
|
| Income Tax Expense |
$1.60 M
|
-$1.83 M
|
$5.70 M
|
$1.04 M
|
$1.21 M
|
$3.28 M
|
$514,000.00
|
-$16.20 M
|
$35,000.00
|
-$2.32 M
|
| Net Income |
-$569.18 M
|
-$606.64 M
|
-$707.42 M
|
-$454.03 M
|
-$186.57 M
|
-$402.73 M
|
-$197.61 M
|
-$302.14 M
|
-$245.87 M
|
-$145.62 M
|
| Net Income Ratio |
-1.02
|
-1.4
|
-1.95
|
-1.29
|
-0.69
|
-3.88
|
-3.84
|
-115.67
|
-1848.68
|
0
|
| EPS |
-6.29 |
-8.25 |
-10.12 |
-6.7 |
-3.07 |
-7.12 |
-3.97 |
-7.12 |
-6.21 |
-3.96 |
| EPS Diluted |
-6.29 |
-8.25 |
-10.12 |
-6.7 |
-3.07 |
-7.12 |
-3.97 |
-7.12 |
-6.21 |
-3.96 |
| Weighted Average Shares Out |
$90.54 M
|
$73.54 M
|
$69.91 M
|
$67.80 M
|
$60.85 M
|
$56.58 M
|
$49.78 M
|
$42.45 M
|
$39.59 M
|
$36.78 M
|
| Weighted Average Shares Out Diluted |
$90.54 M
|
$73.54 M
|
$69.91 M
|
$67.80 M
|
$60.85 M
|
$56.58 M
|
$49.78 M
|
$42.45 M
|
$39.59 M
|
$36.78 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
